In a world where healthcare and pharmaceuticals are no longer just industries but lifelines of nations, the companies that build and engineer the backbone of this sector stand out as silent yet powerful growth drivers. One such player is Fabtech Technologies, now entering the capital markets with its IPO.
Fabtech Technologies IPO review is designed not just as a surface-level glance, but as a deeper business and revenue model analysis. By the end of this three-part series, you will understand:
- How Fabtech earns its revenues and the unique structure of its business model.
- Where the company stands financially and what growth trajectory it has set.
- Why this IPO could be significant for investors seeking exposure to pharma infrastructure and global turnkey solutions.
If you are curious about how engineering expertise translates into consistent revenues across 62+ countries and how Fabtech has positioned itself in this niche but high-growth domain, Fabtech Technologies IPO review will give you those insights.
Table of Contents
Fabtech Technologies IPO: Company Overview & Legacy
Founded with the vision of enabling end-to-end pharma, biotech, and healthcare infrastructure, Fabtech Technologies has today expanded into a truly global turnkey engineering solutions provider. Headquartered in India, the company has successfully executed 51 projects across more than 62 countries as of July 2025.
Its reach extends across emerging markets such as Bangladesh, Kenya, Nigeria, Saudi Arabia, and Ethiopia, as well as developed hubs like the USA and Europe. This global presence not only diversifies risk but also places Fabtech in regions where healthcare infrastructure demand is accelerating.
The company has also undergone strategic restructuring to sharpen focus areas – consolidating its export division and leveraging subsidiaries such as:
- FT Institutions
- FABL International Technologies LLP
- Fabtech Technologies LLC (Sharjah) – which further owns FTS Cleanrooms LLC
Promoter leadership remains strong with Aasif Ahsan Khan, Aarif Ahsan Khan, Hemant Mohan Anavkar, and Manisha Hemant Anavkar, together holding over 95% of pre-IPO equity. This demonstrates both confidence and skin-in-the-game from the founding team.
Fabtech Technologies IPO Review: Business Model
At its core, Fabtech is a turnkey pharma engineering solutions provider. What does this mean? Unlike traditional contractors who focus on isolated parts of a project, Fabtech delivers end-to-end solutions covering:
- Consulting & Design – understanding client needs and planning facilities.
- Engineering & Procurement – sourcing critical equipment (cleanrooms, HVAC, utilities, process equipment).
- Installation & Commissioning – complete execution, testing, and qualification.
- Validation & Certification – ensuring global compliance and operational excellence.
This integrated model is further strengthened by related group entities and partnerships that handle everything from modular panels to injectables equipment. The company’s “one-stop solution” positioning reduces dependency for clients, making Fabtech a preferred partner for large-scale projects.
📌 Case Studies as Proof of Execution:
- In Nigeria, Fabtech transformed a stalled pharma unit into a multi-dosage global-standard facility in just 15 months.
- In Saudi Arabia, despite political and financial hurdles, Fabtech completed a facility for oncology and injectables, proving its reliability even in challenging environments.
Such execution capability not only builds trust with global clients but also establishes Fabtech as an agile and dependable partner in mission-critical sectors.
Revenue Streams & Geography Mix
Fabtech Technologies has carefully built a dual-engine revenue model that balances scale with stability:
a) Turnkey Engineering Projects
The backbone of Fabtech’s business lies in end-to-end turnkey pharma projects, where the company delivers a facility ready for commercial production. These contracts typically span INR 50 crore to over INR 200 crore, covering everything from consulting, design, procurement, installation, commissioning, validation to training.
- In the last three fiscal years, turnkey projects have contributed over 80% of revenues, reaffirming Fabtech’s positioning as a one-stop solutions partner rather than a fragmented contractor.
- Such contracts ensure multi-quarter revenue visibility, high client stickiness, and stronger margins.
- Case studies like Nigeria’s multi-dosage revival project and Saudi Arabia’s oncology and injectables facility demonstrate Fabtech’s ability to execute even under political and financial constraints.
b) Standalone Equipment & Services
Apart from turnkey projects, Fabtech also earns from specialized equipment and services — such as bio clean air systems, clean water solutions, process equipment, isolators, and modular panels.
- These projects typically close within 3–6 months, helping Fabtech maintain steady cash flows between larger contracts.
- They also act as entry-level engagements with new clients, which often scale into larger turnkey mandates.
c) Order Book Visibility
As of 31 July 2025, Fabtech reported an order book of INR 904.41 crore, which is nearly 3x FY25 revenue (INR 326.7 crore) — offering a strong growth runway.
- Top 5 customers contribute ~62% of the order book.
- Top 10 customers contribute ~87%.
- While this shows concentration, it also indicates Fabtech’s ability to secure mega, repeat contracts from trusted global players — a hallmark of niche project-driven businesses.
d) Geographic Diversification
Fabtech’s presence in 62+ countries ensures risk balancing across markets.
- South Asia: Strong demand from Bangladesh, Sri Lanka, and India.
- Middle East: Large-scale oncology and specialty facilities in Saudi Arabia, UAE, Palestine.
- Africa: Projects in Nigeria, Kenya, Ethiopia — where Fabtech is among the few credible turnkey providers.
- Other hubs: Presence in Turkey, Morocco, Nicaragua, USA adds credibility and global positioning.
💡 In essence, Fabtech’s revenues are powered by large, long-cycle turnkey projects for scale and shorter equipment/services projects for resilience — a balanced and scalable business model.
Fabtech Technologies IPO Review: Financial Performance & Margins
Fabtech’s financials reflect high growth, expanding margins, and efficient capital use.
| Metric | FY23 | FY24 | FY25 | Trend/Comment |
|---|---|---|---|---|
| Revenue from Operations | 193.8 | 226.1 | 326.7 | ~30% CAGR over 3 yrs |
| Net Profit | 21.7 | 27.2 | 46.4 | 2x growth in 3 yrs |
| Net Margin (%) | 11.2% | 12.0% | 14.2% | Expanding profitability |
| EPS (INR) | 6.74 | 8.43 | 14.34 | Strong shareholder value accretion |
| ROCE (%) | 29.4 | 28.8 | 24.5 | Healthy, though moderating |
| RONW (%) | 24.4 | 20.6 | 26.8 | Strong return ratios |
| Debt/Equity | 0.39 | 0.07 | 0.32 | Comfortable leverage |
- FY25 included INR 17.8 Cr exceptional income, boosting profit further.
- Even excluding one-offs, profitability remains on a healthy upward curve.
- At IPO pricing (INR 181–191), Fabtech trades at a P/E of 12.6–13.3x FY25 EPS, which is attractive vs sector peers.
Fabtech Technologies IPO Review: Strengths & Competitive Advantage
Fabtech’s positioning is not just about revenues; it’s about strategic advantages that build long-term moat:
- Global Scale with Emerging Market Leadership – Presence in 62 countries ensures revenue resilience and growth opportunities.
- Integrated Turnkey Solutions – From design to certification, Fabtech provides the full chain under one roof — reducing client risks and ensuring loyalty.
- Proven Execution Track Record – Successfully delivered projects in challenging geographies like Nigeria and Saudi Arabia.
- High Barriers to Entry – Pharma infrastructure projects demand deep technical know-how, which limits competition.
- Local Partnerships & JVs – Collaborations in regions like Egypt reduce costs, speed up execution, and enhance customer trust.
- Promoter Commitment – Pre-IPO promoter holding of 95.6% reflects strong alignment with shareholders’ interests.
Together, these strengths underline Fabtech’s ability to scale profitably, expand into new geographies, and remain a trusted partner in the global pharma ecosystem.
Fabtech Technologies IPO Analysis: Risks & Challenges
Even with its strong fundamentals, Fabtech Technologies faces certain risks that investors should be mindful of:
- Working Capital Intensity – Turnkey pharma infra projects demand significant upfront investments in raw material, utilities, and equipment. This can pressure liquidity if payments are delayed.
- Geopolitical Exposure – Operations in Africa and the Middle East expose the company to risks of political instability, foreign exchange volatility, and funding shortages.
- Insurance Coverage Gap – In FY25, ~88% of insurable assets were left uninsured, which leaves the company exposed to unforeseen losses.
- Competitive Market – The turnkey engineering solutions industry is fragmented. Global engineering players remain strong competitors, although Fabtech’s niche expertise gives it a clear edge.
Still, Fabtech has consistently demonstrated its ability to execute under constraints (e.g., completing Saudi Arabia projects despite client funding issues), showing resilience in managing risks effectively.
IPO Details & Utilisation of Funds
IPO Snapshot
- Issue Dates: 29 Sept – 1 Oct 2025
- Price Band: INR 181 – 191 per share
- Lot Size: 75 shares (min. investment ~INR 14,325)
- Fresh Issue: 1.20 Cr shares (~INR 218–230 Cr)
- Offer for Sale (OFS): Nil – promoters are not offloading any stake
- Listing: BSE, NSE
- Retail Quota: 35%
Use of Proceeds
| Particulars | Amount | Purpose |
|---|---|---|
| Working Capital | 127 | To fund project cycle requirements |
| Acquisitions | 30 | Pursuing inorganic growth initiatives |
| General Corporate Purposes | Balance | Strengthening operations & expansion |
Conclusion
Fabtech Technologies has positioned itself as a trusted global partner in pharma engineering solutions, executing projects in 62 countries with a growing order book of INR 904.4 Cr (~3x FY25 revenue). Financials reflect robust growth — revenues rose from INR 193.8 Cr in FY23 to INR 326.6 Cr in FY25, while net profit more than doubled to INR 46.4 Cr during the same period.
Valuations appear attractive:
- EPS (FY25): INR 14.34
- P/E: 12.6x – 13.3x (vs industry ~20–25x)
- RONW: 26.8%
- Debt/Equity: 0.32
The absence of an OFS highlights promoter confidence, as all proceeds are aimed at fueling growth through working capital and acquisitions. While risks like client concentration and geopolitical exposure exist, Fabtech’s track record of navigating complex projects under challenging environments provides reassurance.
For investors seeking long-term exposure to the pharma capex and healthcare infrastructure growth story, Fabtech Technologies IPO offers a rare mix of scale, credibility, and attractive pricing.
For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription stay tuned to IPO Central.